There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Baxter International (BAX) and Aldeyra Therapeutics (ALDX) with bullish sentiments.
Baxter International (BAX)
Oppenheimer analyst Suraj Kalia maintained a Buy rating on Baxter International today and set a price target of $100.00. The company’s shares closed last Thursday at $77.86.
According to TipRanks.com, Kalia is a 4-star analyst with an average return of 9.0% and a 56.7% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Cardiovascular Systems, and Irhythm Technologies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Baxter International with a $90.38 average price target.
See today’s analyst top recommended stocks >>
Aldeyra Therapeutics (ALDX)
In a report released today, Matthew Cross from Alliance Global Partners maintained a Buy rating on Aldeyra Therapeutics, with a price target of $32.00. The company’s shares closed last Thursday at $12.40.
According to TipRanks.com, Cross is a 4-star analyst with an average return of 14.6% and a 44.2% success rate. Cross covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Syros Pharmaceuticals, and Aptose Biosciences.
Currently, the analyst consensus on Aldeyra Therapeutics is a Strong Buy with an average price target of $24.75, implying a 109.7% upside from current levels. In a report issued on January 28, JonesTrading also initiated coverage with a Buy rating on the stock with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
